A new analysis of statin side effects has found that only four commonly reported adverse events are likely caused by the cholesterol-lowering drugs, according to research published this week. The study, conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration at the University of Oxford, examined 66 potential side effects listed on statin packaging, significantly narrowing the scope of attributed health problems.
The CTT Collaboration, established in 1994, conducts meta-analyses of individual participant data from large-scale, randomized controlled trials of lipid intervention treatments. The group’s perform is coordinated jointly by the Clinical Trial Service Unit & Epidemiological Studies Unit in Oxford and the National Health and Medical Research Council Clinical Trials Centre in Sydney. The impetus for the study stemmed from concerns that statin labels list a wide range of potential side effects, many of which may not be causally linked to the medication, potentially discouraging patients from taking a vital preventative treatment.
The four side effects definitively linked to statins in the analysis are abnormal liver enzyme levels, other alterations in liver function tests, changes in urine composition, and edema, or swelling. Researchers deliberately excluded well-known side effects like muscle pain, myopathy, increased risk of diabetes, and cerebral hemorrhages, acknowledging these exist but are rarer than commonly perceived, as demonstrated in previous CTT research conducted a decade ago.
“If a patient reports feeling something unusual, like a tingling finger, that can end up on the label,” explained Professor Raul Dias dos Santos, a cardiologist at the Einstein Hospital Israelita and professor at the University of São Paulo, in comments regarding the study’s methodology. Professor dos Santos was not directly involved in the research but authored the editorial accompanying the publication in The Lancet.
The process of determining which side effects appear on drug labels involves initial observations during clinical trials, where patients are asked about any symptoms they experience. After a drug is released, pharmacovigilance systems allow individuals to report adverse events. If a significant number of people report the same complaint, it may be added to the label, regardless of whether a direct link to the medication can be established.
The CTT Collaboration’s recent work builds on decades of research focused on statin therapy, encompassing data from 28 major statin trials and approximately 175,000 participants. The group has expanded its analysis beyond major vascular events, cancers, and mortality to include a comprehensive assessment of all potential adverse effects, utilizing standardized data formats like the Clinical Data Interchange Standards Consortium Study Data Tabulation Model (CDISC SDTM) and the Medical Dictionary for Regulatory Activities (MedDRA).
